Cargando…

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

Sustained virologic response at posttreatment Week 12 (SVR12) is the widely accepted efficacy endpoint for direct‐acting antiviral agents. Those with hepatitis C virus (HCV) are presenting younger with milder liver disease, potentially reducing need for long‐term liver posttreatment monitoring. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gane, Edward, de Ledinghen, Victor, Dylla, Douglas E., Rizzardini, Giuliano, Shiffman, Mitchell L., Barclay, Stephen T., Calleja, Jose Luis, Xue, Zhenyi, Burroughs, Margaret, Gutierrez, Julio A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292745/ https://www.ncbi.nlm.nih.gov/pubmed/34448313 http://dx.doi.org/10.1111/jvh.13600

Ejemplares similares

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
por: Zamor, Philippe J., et al.
Publicado: (2021)

Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
por: Manabe, Takushi, et al.
Publicado: (2022)

High Real-World Sustained Virologic Response Rate with Glecaprevir/Pibrentasvir at a Racially Diverse Urban Academic Medical Center
por: Martin, Michelle T., et al.
Publicado: (2022)

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
por: Brown, Robert S., et al.
Publicado: (2022)

1979. Time to Viral Suppression Does Not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir for 8 Weeks
por: Sarrazin, Christoph, et al.
Publicado: (2018)

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
por: Flamm, Steven L., et al.
Publicado: (2020)

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study
por: Martinello, Marianne, et al.
Publicado: (2023)

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
por: Feld, Jordan J., et al.
Publicado: (2022)

Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial
por: Madsen, Lone W., et al.
Publicado: (2022)

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
por: Naganuma, Atsushi, et al.
Publicado: (2019)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection
por: van Paassen, Pien M., et al.
Publicado: (2023)

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
por: Reau, Nancy, et al.
Publicado: (2023)

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
por: Tamai, Hideyuki, et al.
Publicado: (2014)

Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study
por: Aghemo, Alessio, et al.
Publicado: (2023)

Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin
por: Thompson, Alex, et al.
Publicado: (2014)

Combined Pre- and Posttreatment of Paraoxon Exposure
por: Lorke, Dietrich E, et al.
Publicado: (2020)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017)

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
por: Forns, Xavier, et al.
Publicado: (2021)

Spatiotemporal Changes Posttreatment in Peripheral Arterial Disease
por: Myers, Sara A., et al.
Publicado: (2015)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
por: Fontana, Robert J., et al.
Publicado: (2019)

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy
por: Andreoni, Massimo, et al.
Publicado: (2021)

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
por: Cornberg, Markus, et al.
Publicado: (2022)

Durability of Sustained Virologic Response in Chronic Hepatitis C
por: Uyanikoglu, Ahmet, et al.
Publicado: (2013)

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir/Velpatasvir
por: Abi-Saleh, Simon P, et al.
Publicado: (2023)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021)

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting
por: Lu, Yung-Hsin, et al.
Publicado: (2022)

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
por: Flamm, Steven, et al.
Publicado: (2018)

Reversal of Myoblast Aging by Tocotrienol Rich Fraction Posttreatment
por: Lim, Jing Jye, et al.
Publicado: (2013)

Adipocyte-Like Differentiation in a Posttreatment Embryonal Rhabdomyosarcoma
por: Balitzer, Dana, et al.
Publicado: (2015)

A Systematic Review of Tests for Postcolposcopy and Posttreatment Surveillance
por: Clarke, Megan A., et al.
Publicado: (2020)

Contrast Sensitivity Loss in Patients With Posttreatment Lyme Disease
por: Rebman, Alison W., et al.
Publicado: (2021)

Forecasting Posttreatment Outcome of Hallux Valgus Surgery Patients
por: Sawah, Amjad, et al.
Publicado: (2021)

Is Coronal Restoration a Predictor of Posttreatment Apical Periodontitis?
por: Persic Bukmir, Romana, et al.
Publicado: (2021)

Elite and posttreatment controllers, two facets of HIV control
por: Mastrangelo, Andrea, et al.
Publicado: (2022)

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oovg8173eomt6svt4h7pr0esq9